Table 3.
Prematching Receiver Operating Characteristic Curve Analysis of NT‐proBNP, eGFR, and hs‐CRP for the Prediction of CRS1
| Cutoff Value | Abnormality (n, %)a | AUC | P Value | 95% CI | Sensitivity | Specificity | Youden Index | ||
|---|---|---|---|---|---|---|---|---|---|
| No‐CRS1 | CRS1 | ||||||||
| eGFR at admission, mL/(min·1.73 m2) | 71.29 | 550 (28.7) | 142 (80.2) | 0.828 | <0.001 | 0.811 to 0.844 | 0.8079 | 0.7131 | 0.521 |
| NT‐proBNP at admission, pg/mL | 2573 | 385 (22.2) | 120 (74.5) | 0.813 | <0.001 | 0.777 to 0.849 | 0.7453 | 0.7782 | 0.524 |
| hs‐CRP at admission, mg/L | 8.03 | 806 (43.0) | 125 (76.2) | 0.693 | <0.001 | 0.653 to 0.733 | 0.7622 | 0.5704 | 0.333 |
| NT‐proBNP +eGFR+ hs‐CRP | ··· | ··· | ··· | 0.856 | <0.001 | 0.825 to 0.886 | ··· | ··· | ··· |
AUC indicates area under the receiver operating characteristic curve; CI, confidence interval; CRS1, cardiorenal syndrome type 1; eGFR, estimated glomerular filtration rate; hs‐CRP, high‐sensitivity C‐reactive protein; NT‐proBNP, amino‐terminal pro–brain natriuretic peptide.
a
Abnormal biomarkers levels were defined as eGFR≤71.29 mL/(min·1.73 m2), NT‐proBNP≥2573 pg/mL, and hs‐CRP≥8.03 mg/L individually.